1
|
Aksoy S, Dizdar [, Dede D, Arslan C, Dogan E, Tapan [, Özkan [, Hesenov S, Cinel M, Yaman S, Kizilarslan M, Özisik Y, Altundag K. The Frequency and Determinants of Metabolic Syndrome in Patients with Operable Stage I-III Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Metabolic syndrome is a cluster of multiple risk factors including obesity, insulin resistance, hypertriglyceridemia, low HDL (high density lipoprotein), and hypertension. Metabolic syndrome is associated with an increased risk of breast cancer. We evaluated the frequency and determinants of metabolic syndrome in patients with operable stage I-III breast cancer.Methods: In this cross-sectional study we analyzed the frequency and determinants of metabolic syndrome in patients with stage I-III breast cancer. Metabolic syndrome was defined according to NCEP (National Cholesterol Education Program) definitions. Data on metabolic syndrome criteria were collected along with demographic data, tumor size, grade, lymph node, estrogen, progesterone, HER2 status, grade and history of chemotherapy/endocrine therapy.Results: A total of 331 patients were analyzed. Median age was 50.0 years (range 20-84 years). Eighty-five patients were using tamoxifen, 98 patients were using aromatase inhibitors and the remaining 148 patients were not receiving hormonal therapy (newly diagnosed and/or triple-negative patients). According to the NCEP criteria 48.0% of the patients had metabolic syndrome. More patients receiving aromatase inhibitors had metabolic syndrome than those receiving tamoxifen (60.2% vs. 37.6%, p = 0.008). The frequency of MS among those not taking any hormonal therapy was 45.9%. Additionally, post-menopausal patients had higher rate of MS compared to pre-menopausal ones (53.4% vs. 25.0% p=<0.001). Patients with HER2 positive tumors and patients who had a history of oral contraceptive use had lower rates of metabolic syndrome than those with HER2 negative tumors and no oral contraceptive use, respectively (40,0% vs. 53,7% for HER2, p=0.028 and 32,6% vs. 50,3% for oral contraceptive use, p=0.034).There was no significant correlation between the presence of metabolic syndrome and estrogen/progesterone receptor status, tumor size, nodal status, stage, grade, adjuvant chemotherapy, hormone replacement therapy, smoking history.Conclusions: Nearly half of the patients with stage I-III breast cancer had metabolic syndrome. Adjuvant aromatase inhibitor therapy was found to be associated with higher rate of metabolic syndrome whereas history of oral contraceptive use and HER2 positivity were associated with lower rate. Whether the aromatase inhibitors contribute the development of metabolic syndrome or not needs to be elucidated by future prospective studies.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5121.
Collapse
Affiliation(s)
- S. Aksoy
- 1Hacettepe University Institute of Oncology, Turkey
| | - [. Dizdar
- 1Hacettepe University Institute of Oncology, Turkey
| | - D. Dede
- 1Hacettepe University Institute of Oncology, Turkey
| | - C. Arslan
- 1Hacettepe University Institute of Oncology, Turkey
| | - E. Dogan
- 1Hacettepe University Institute of Oncology, Turkey
| | - [. Tapan
- 2Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - [. Özkan
- 2Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - S. Hesenov
- 2Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - M. Cinel
- 2Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - S. Yaman
- 2Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - M. Kizilarslan
- 2Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - Y. Özisik
- 1Hacettepe University Institute of Oncology, Turkey
| | - K. Altundag
- 1Hacettepe University Institute of Oncology, Turkey
| |
Collapse
|